Works matching IS 01676997 AND DT 2016 AND VI 34 AND IP 6

Results: 15

A phase I trial of cabozantinib and gemcitabine in advanced pancreatic cancer.

Published in:

Investigational New Drugs, 2016, v. 34, n. 6, p. 733, doi. 10.1007/s10637-016-0376-1

By:

Zhen, David;
Griffith, Kent;
Ruch, Joshua;
Camphausen, Kevin;
Savage, Jason;
Kim, Edward;
Sahai, Vaibhav;
Simeone, Diane;
Zalupski, Mark

Publication type:

Article

A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2016, v. 34, n. 6, p. 740, doi. 10.1007/s10637-016-0377-0

By:

Grilley-Olson, J.;
Bedard, P.;
Fasolo, A.;
Cornfeld, M.;
Cartee, L.;
Razak, A.;
Stayner, L.-A.;
Wu, Y.;
Greenwood, R.;
Singh, R.;
Lee, C.;
Bendell, J.;
Burris, H.;
Del Conte, G.;
Sessa, C.;
Infante, J.

Publication type:

Article

Sunitinib -induced sudden hearing loss.

Published in:

Investigational New Drugs, 2016, v. 34, n. 6, p. 792, doi. 10.1007/s10637-016-0378-z

By:

Dekeister, Kathleen;
Graillot, Emmanuelle;
Durbec, Mickaël;
Scoazec, Jean-Yves;
Walter, Thomas

Publication type:

Article

Comprehensive analysis of clinical development and regulatory submission promotion schemes for oncologic drugs as the Japanese national projects.

Published in:

Investigational New Drugs, 2016, v. 34, n. 6, p. 777, doi. 10.1007/s10637-016-0380-5

By:

Nagai, Sumimasa;
Ozawa, Keiya

Publication type:

Article

Phase I study of NK105, a nanomicellar paclitaxel formulation, administered on a weekly schedule in patients with solid tumors.

Published in:

Investigational New Drugs, 2016, v. 34, n. 6, p. 750, doi. 10.1007/s10637-016-0381-4

By:

Mukai, Hirofumi;
Kato, Ken;
Esaki, Taito;
Ohsumi, Shouzou;
Hozomi, Yasuo;
Matsubara, Nobuaki;
Hamaguchi, Tetsuya;
Matsumura, Yasuhiro;
Goda, Rika;
Hirai, Takayuki;
Nambu, Yoshihiro

Publication type:

Article

Adding checkpoint inhibitors to tyrosine kinase inhibitors targeting EGFR/ALK in non-small cell lung cancer: a new therapeutic strategy.

Published in:

Investigational New Drugs, 2016, v. 34, n. 6, p. 794, doi. 10.1007/s10637-016-0383-2

By:

Tabchi, Samer;
Kourie, Hampig;
Kattan, Joseph

Publication type:

Article

Successful treatment with afatinib after gefitinib- and erlotinib-induced hepatotoxicity.

Published in:

Investigational New Drugs, 2016, v. 34, n. 6, p. 797, doi. 10.1007/s10637-016-0384-1

By:

Ueda, Hiroto;
Hayashi, Hidetoshi;
Kudo, Keita;
Takeda, Masayuki;
Nakagawa, Kazuhiko

Publication type:

Article

Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients.

Published in:

Investigational New Drugs, 2016, v. 34, n. 6, p. 760, doi. 10.1007/s10637-016-0385-0

By:

Di Desidero, Teresa;
Derosa, Lisa;
Galli, Luca;
Orlandi, Paola;
Fontana, Andrea;
Fioravanti, Anna;
Marconcini, Riccardo;
Giorgi, Mario;
Campi, Beatrice;
Saba, Alessandro;
Lucchesi, Sara;
Felipetto, Renato;
Danesi, Romano;
Francia, Giulio;
Allegrini, Giacomo;
Falcone, Alfredo;
Bocci, Guido

Publication type:

Article

Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC).

Published in:

Investigational New Drugs, 2016, v. 34, n. 6, p. 771, doi. 10.1007/s10637-016-0386-z

By:

Parimi, Sunil;
Eliasziw, Misha;
North, Scott;
Trudeau, Marc;
Winquist, Eric;
Chi, Kim;
Ruether, Dean;
Cheng, Tina;
Eigl, Bernhard

Publication type:

Article

The novel kinase inhibitor ponatinib is an effective anti-angiogenic agent against neuroblastoma.

Published in:

Investigational New Drugs, 2016, v. 34, n. 6, p. 685, doi. 10.1007/s10637-016-0387-y

By:

Whittle, Sarah;
Patel, Kalyani;
Zhang, Linna;
Woodfield, Sarah;
Du, Michael;
Smith, Valeria;
Zage, Peter

Publication type:

Article

Comparative effects of doxorubicin and a doxorubicin analog, 13-deoxy, 5-iminodoxorubicin (GPX-150), on human topoisomerase IIβ activity and cardiac function in a chronic rabbit model.

Published in:

Investigational New Drugs, 2016, v. 34, n. 6, p. 693, doi. 10.1007/s10637-016-0388-x

By:

Frank, Nicole;
Cusack, Barry;
Talley, Todd;
Walsh, Gerald;
Olson, Richard

Publication type:

Article

A retrospective analysis of 14 consecutive Chinese patients with unresectable or metastatic alveolar soft part sarcoma treated with sunitinib.

Published in:

Investigational New Drugs, 2016, v. 34, n. 6, p. 701, doi. 10.1007/s10637-016-0390-3

By:

Li, Ting;
Wang, Lei;
Wang, Huijie;
Zhang, Shujuan;
Atikan·Kawuli;
Zhang, Xiaowei;
Luo, Zhiguo;
Wang, Chunmeng

Publication type:

Article

Propolis extracts from the northern region of Thailand suppress cancer cell growth through induction of apoptosis pathways.

Published in:

Investigational New Drugs, 2016, v. 34, n. 6, p. 707, doi. 10.1007/s10637-016-0392-1

By:

Khacha-ananda, Supakit;
Tragoolpua, Khajornsak;
Chantawannakul, Panuwan;
Tragoolpua, Yingmanee

Publication type:

Article

New water-soluble palladium(II) complexes of lidocaine and phenylcyanamide derivative ligands: cytotoxicity and cellular response mechanisms.

Published in:

Investigational New Drugs, 2016, v. 34, n. 6, p. 723, doi. 10.1007/s10637-016-0393-0

By:

Tabrizi, Leila;
Chiniforoshan, Hossein

Publication type:

Article

Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry.

Published in:

Investigational New Drugs, 2016, v. 34, n. 6, p. 677, doi. 10.1007/s10637-016-0373-4

By:

Cho, Jinhyun;
Ahn, Soomin;
Yoo, Kwai;
Kim, Jung;
Choi, Sang-Hee;
Jang, Kee-Taek;
Lee, Jeeyun

Publication type:

Article